Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix CEO Discusses Significance of WellMed Adoption of NC-stat® DPNCheck™
Importance of Managed Care Sector is Highlighted
View HTML
Toggle Summary NeuroMetrix Announces WellMed Medical Management’s Integration of NC-stat® DPNCheck™ Into Their Patient Evaluation Program
NeuroMetrix Announces WellMed Medical Management’s Integration of NC-stat® DPNCheck™ Into Their Patient Evaluation Program WALTHAM, Mass. --(BUSINESS WIRE)--May. 15, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the
View HTML
Toggle Summary NeuroMetrix to Showcase Test for Diabetic Neuropathy at International Meeting
Malvern (U.K.) Diabetic Foot Conference on May 9-12, 2012
View HTML
Toggle Summary NeuroMetrix Officers Interviewed on Plans for Diabetes Market
Business Focus on Diabetes-Related Nerve Damage
View HTML
Toggle Summary NeuroMetrix Reports Q1 2012 Results
Operational and Strategic Progress in Diabetes Business
View HTML
Toggle Summary NeuroMetrix to Support Study at the Joslin Diabetes Center
Investigating the Impact of Intensive Diabetes Management on Diabetic Peripheral Neuropathy
View HTML
Toggle Summary NeuroMetrix Files 510(k) for SENSUS(TM) Pain Therapy Device
NeuroMetrix Files 510(k) for SENSUS(TM) Pain Therapy Device WALTHAM, Mass., Apr 18, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today that it has filed a premarket
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for 2012 First Quarter Financial Results Conference Call
NeuroMetrix, Inc. Announces Date for 2012 First Quarter Financial Results Conference Call WALTHAM, Mass., Apr 17, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012 first quarter financial results before the opening of the market on April 24, 2012.
View HTML
Toggle Summary NeuroMetrix to Exhibit at the Midwest Podiatry Conference
NeuroMetrix to Exhibit at the Midwest Podiatry Conference WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 10, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today that it will exhibit at the
View HTML
Toggle Summary NeuroMetrix CEO Interviewed on CEONEWS.Tv
Company is Addressing Diabetes-Related Nerve Disease
View HTML